Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC | Nature Reviews Clinical Oncology
Frontiers | Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer
JTO & JTO CRR on Twitter: "In CheckMate 227, nivolumab plus ipilimumab prolonged overall survival versus chemotherapy in patients w/tumor programmed death-ligand 1 greater than or equal to 1% (primary end point)
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer | NEJM
Immunotherapy in mNSCLC - ASCO 2021: Key NSCLC Studies - Lung Cancer - 2021 ASCO Virtual Annual Meeting - Health Disparities - Clinical Care Options
First-line Nivolumab Plus Ipilimumab is Safe
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis - The Lancet Oncology
Kaplan-Meier curves after matching adjustment for (A) overall survival... | Download Scientific Diagram
ISPOR 2022: Mixture-Cure Modelling of the Overall Survival Outcomes of Patients with Advanced Non-Small Cell Lung Cancer (ANSCLC) Receiving Nivolumab + Ipilimumab in CheckMate-227
New CheckMate-227 5-Year Data Show Substantial Survival Benefit of Combination Immunotherapy for Metastatic Non–Small Cell Lung Cancer
Pharmaceuticals | Free Full-Text | First line Immunotherapy for Non-Small Cell Lung Cancer
ASCO 2022: Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for metastatic non–small cell lung cancer (NSCLC): Results from CheckMate 227.
February 6, 2018 Pivotal Phase 3 CheckMate -227 Study Demonstrates Superior Progression-Free Survival (PFS) with the Opdivo Plus
Comparisons between the CheckMate 227 trial and simulation, overall... | Download Scientific Diagram
ASCO 2020 Lung Cancer Highlights - Journal of Oncology Navigation & Survivorship
Immunotherapy Advances - ASCO 2020: Key Lung Cancer Studies - Lung Cancer - 2020 ASCO Annual Meeting - Oncology - Clinical Care Options
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA | SpringerLink
ESMO 2022: Treatment switching adjustment of overall survival in the CheckMate 227 clinical trial of nivolumab plus ipilimumab versus chemotherapy in first-line treatment of patients with advanced non-small cell lung cancer
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden | NEJM
Immunotherapy in mNSCLC - ASCO 2021: Key NSCLC Studies - Lung Cancer - 2021 ASCO Virtual Annual Meeting - Health Disparities - Clinical Care Options
Immunotherapy in Advanced Lung Cancer
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial - The Lancet Oncology
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer | NEJM
CheckMate 568: Efficacy and Biomarker Analysis for Nivolumab and Ipilimumab in NSCLC - ILCN.org (ILCN/WCLC)
Immunotherapy Advances - ASCO 2020: Key Lung Cancer Studies - Lung Cancer - 2020 ASCO Annual Meeting - Oncology - Clinical Care Options
Bristol might play a role in front-line lung cancer after all | Evaluate
